<DOC>
	<DOCNO>NCT00559091</DOCNO>
	<brief_summary>The purpose study determine ribavirin ( drug commonly use treat hepatitis C ) also activity treatment patient refractory relapse acute myeloid leukemia ( AML ) M4 M5 subtype .</brief_summary>
	<brief_title>A Study Ribavirin Treat M4 M5 Acute Myelocytic Leukemia</brief_title>
	<detailed_description>The eukaryotic translation initiation factor eIF4E dysregulated many human malignancy , include subset myeloid leukemia ( M4/M5 AML blast crisis CML ) . eIF4E overexpression lead oncogenic transformation . Ribavirin impede eIF4E mediate transformation vitro , primary human specimens animal model . While ribavirin use extensively treatment viral hepatitis C safety profile well define , never use patient AML . This study establish efficacy safety ribavirin M4/M5 AML patient . In addition , study also include correlative study determine effect ribavirin eIF4E activity eIF4E relate pathway M4/M5 AML patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>A diagnosis acute myeloid leukemia ( AML ) , either M4 M5 subtype de novo result transformation MDS myeloproliferative disorder . Patients AML ( ) fail primary therapy define fail two induction chemotherapy , ( b ) relapse ( c ) suitable intensive induction chemotherapy eligible . OR Patients AML blast crisis CML suitable candidate intensive induction chemotherapy fail imatinib mesylate OR Patients secondary AML MDS suitable candidate intensive induction chemotherapy . ECOG 0,1,2 , 3 Life expectancy &gt; 12 week . Adequate renal hepatic function Uncontrolled central nervous system involvement AML Active cardiovascular disease define NYHA class IIIIV categorization . Intercurrent illness medical condition preclude safe administration ribavirin . Received previous therapy within 28 day prior study entry.Hydrea permit must stop 7 day prior start study drug . Known infection HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute myelocytic leukemia</keyword>
	<keyword>leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>M4</keyword>
	<keyword>M5</keyword>
</DOC>